Category Archives: Op-Ed

UK Postpones Decision on Value-Based Assessment — Again

By Leela Barham. Value-based Pricing (VBP) was first discussed as far back as 2007 by the UK’s consumer authority, the now defunct Office of Fair Trading (OFT).  The general concept of VBP was to set almost provisional prices based on the expected value of new medicines using immature data, with provisions to ‘correct’ the price […]
Also posted in Europe, Global, Guest Blog, pricing | Tagged , , , , , , | Leave a comment

Email Marketing's Growing Maturity

Email marketing is still very much with us, despite much talk of its demise. But, writes Peter Houston, it has moved on from its “spammy” adolescence. Scary tales of The-Next-Big-Social-Thing killing off the first digital marketing blockbuster have been building for years. McKinsey’s November 2013  iConsumer survey reported a 20 percent decline in email usage […]
Also posted in Marketing, Patient Communication, social media, Strategy | Tagged , , | Leave a comment

What's the Future of European Health Policy?

What can be gleaned about the direction that health policy will take for the next five years under the new European Commission, scheduled to take office at the beginning of November? Peter O’ Donnell address this question in his new Applied Clinical Trials column here.
Also posted in Europe, Global, Guest Blog, healthcare, Regulatory | Tagged , , | Leave a comment

PPRS Payments Now Worth £150m in the UK

By Leela Barham. A second payment has now been made under the UK’s Pharmaceutical Price Regulation Scheme (PPRS). Adding a further £76m to the £74m for the first quarter of 2014, the payments received by the Department of Health (DH) now total £150m (US$244m).  Payments are a new feature of the long-standing voluntary PPRS. The […]
Also posted in Europe, Guest Blog, pricing, Regulatory | Tagged , , | Leave a comment

Managing High-Priced, US Biotech Rxs in Canada

As the “Saga of Sovaldi” continues to unfold in the U.S., and Congress, insurers, providers, and the U.S. Rx manufacturer, Gilead, hurl charges back and forth at each other, it’s pretty clear the situation will only continue to deteriorate. However, as you look north of the American border, it’s striking how Canadian healthcare entities are managing […]
Also posted in pricing | Tagged , , , , | Leave a comment
  • Categories

  • Meta